WebMar 1, 2024 · ELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: … WebNov 20, 2024 · Elahere is a first-in-class antibody-drug conjugate directed against FRα, a cell-surface protein highly expressed in ovarian cancer. The antibody is a chimeric IgG1 directed against FRα. The small molecule, DM4, is a microtubule inhibitor designed to kill the targeted cancer cells. It is attached to the antibody via a cleavable linker.
NDC 72903-853 Elahere Injection, Solution Intravenous
WebDec 12, 2024 · ELAHERE™ was approved by the U.S. Food and Drug Administration (FDA) on November 14, 2024, under the FDA's accelerated approval program based on objective response rate and duration of response data from the pivotal SORAYA trial. The SORAYA trial was a single-arm study in 106 patients with platinum-resistant ovarian cancer whose … WebHealthcare Common Procedure Coding System (HCPCS)1,2 ICD-10-CM diagnosis codes3-5 Since ELAHERE does not yet have a permanent HCPCS code assigned, a temporary J-code can be used on the CMS-1500 form if billing in the physician’s office. Payer … trestles clothing company website
Starting ELAHERE ELAHERE™ (mirvetuximab …
WebNov 14, 2024 · ELAHERE is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer. Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin ® Use. … WebNov 22, 2024 · The Food and Drug Administration (FDA) approval of Elahere (mirvetuximab soravtansine-gynx) is a significant step forward for the treatment of patients with platinum-resistant ovarian cancer, especially since it is the first approval for this patient population since 2014, an expert said. In particular, the FDA recently approved the antibody ... WebFeb 1, 2024 · Outpatient HCPCS (C Codes) C9146 : ... Mirvetuximab soravtansine-gynx (Elahere) is a folate receptor alpha (FR)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FR positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to … tench coat of arms